Sushil Allen Luis

Abstract Inflammatory disease of the pericardium represents a relatively common presentation, especially among the young. For the most part, inflammatory pericardial disease can be expeditiously and effectively managed without significant sequelae. However, some individuals present with severe and recurrent illness, representing significant therapeutic challenges.

This article is available to subscribers. Subscribe now. Already have an account? Sign in Case Records of the Massachusetts General HospitalFree Preview List of authors. October 26, 2023 N Engl J Med 2023; 389:1602-1613 DOI: 10.1056/NEJMcpc2300908 Richard C. Cabot, Founder, Eric S. Rosenberg, M.D., Editor, David M. Dudzinski, M.D., Associate Editor, Meridale V. Baggett, M.D., Associate Editor, Kathy M. Tran, M.D., Associate Editor, Dennis C. Sgroi, M.D., Associate Editor, Jo-Anne O.

Abstract Objective Polypharmacy management of recurrent pericarditis (RP) often involves long-term therapies, often with negative effects. Slow tapering of oral therapies is often required to avoid recurrence.